The Medicines Company was up about 6% in early trading on positive top-line, interim Phase II data for its PCSK9 inhibitor to treat hypercholesterolemia.

Merck KGaA has returned a Phase II multiple sclerosis drug to Apitope.

Daiichi Sankyo has added a preclinical lung cancer collaboration with Dana-Farber Cancer Institute to its fast-growing list of oncology alliances.

AstraZeneca has halted a Phase IIa trial of the severe asthma drug it licensed from Synairgen, wiping 40% off the latter's share price.

The candidate just won a breakthrough designation from the FDA and priority medicine status from the EMA in July, with an FDA submission expected next year.

Daiichi Sankyo has partnered with startup AgonOx to develop novel drugs against an undisclosed immuno-oncology target.

Amgen has become the latest big-name drugmaker to strike a deal to access Nuevolution’s discovery platform.

Boehringer has backed out of the $730 million lung cancer pact it struck with Hanmi Pharmaceutical after reviewing the data and competitive landscape.

Gene therapy player bluebird bio has partnered with German biotech Medigene to develop and commercialize T cell receptor (TCR) immunotherapies against four…